Trials / Completed
CompletedNCT02739373
Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects
Randomized, Double-Blinded, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to measure the amount of study drug (BMS-986189) in the blood and urine and to see if BMS-986189 is safe and well-tolerated in healthy people after a single dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986189 | |
| OTHER | Placebo |
Timeline
- Start date
- 2016-04-18
- Primary completion
- 2016-12-14
- Completion
- 2016-12-14
- First posted
- 2016-04-15
- Last updated
- 2018-02-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02739373. Inclusion in this directory is not an endorsement.